Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led...

Vanguard S&P 500 ETF: A Smart Buy for Long-Term Investors Right Now
10 Best Value Stocks to Buy for the Long Term
RRSPs are great but investments in matter
Muji Expands in Europe with Paris Flagship and Growth Strategy